246 related articles for article (PubMed ID: 7949141)
21. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
[TBL] [Abstract][Full Text] [Related]
22. [Clinical pharmacology of all-trans retinoic acid (ATRA)].
Robak T
Acta Haematol Pol; 1995; 26(3):269-77. PubMed ID: 8525772
[TBL] [Abstract][Full Text] [Related]
23. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
24. Retinoic acid syndrome in acute promyelocytic leukemia.
Sentero D; Hosenpud J
Wis Med J; 1997 Apr; 96(4):35-8. PubMed ID: 9128433
[TBL] [Abstract][Full Text] [Related]
25. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.
Miller WH; Jakubowski A; Tong WP; Miller VA; Rigas JR; Benedetti F; Gill GM; Truglia JA; Ulm E; Shirley M
Blood; 1995 Jun; 85(11):3021-7. PubMed ID: 7756637
[TBL] [Abstract][Full Text] [Related]
26. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
[TBL] [Abstract][Full Text] [Related]
27. Infrequent alterations of the RAR alpha gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines.
Morosetti R; Grignani F; Liberatore C; Pelicci PG; Schiller GJ; Kizaki M; Bartram CR; Miller CW; Koeffler HP
Blood; 1996 May; 87(10):4399-403. PubMed ID: 8639801
[TBL] [Abstract][Full Text] [Related]
28. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Harada M; Ueda R; Ohno R
Leuk Lymphoma; 1998 Nov; 31(5-6):441-51. PubMed ID: 9922035
[TBL] [Abstract][Full Text] [Related]
29. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.
Muindi J; Frankel SR; Miller WH; Jakubowski A; Scheinberg DA; Young CW; Dmitrovsky E; Warrell RP
Blood; 1992 Jan; 79(2):299-303. PubMed ID: 1309668
[TBL] [Abstract][Full Text] [Related]
30. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto.
Specchia G; Lo Coco F; Vignetti M; Avvisati G; Fazi P; Albano F; Di Raimondo F; Martino B; Ferrara F; Selleri C; Liso V; Mandelli F
J Clin Oncol; 2001 Oct; 19(20):4023-8. PubMed ID: 11600603
[TBL] [Abstract][Full Text] [Related]
31. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
32. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
[TBL] [Abstract][Full Text] [Related]
33. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
34. Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Hou KZ; Liu YP; Yu P
Chin Med Sci J; 2006 Sep; 21(3):171-4. PubMed ID: 17086739
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia.
Dreosti LM; Bezwoda W; Gunter K
Leuk Lymphoma; 1994 Apr; 13(3-4):353-6. PubMed ID: 8049655
[TBL] [Abstract][Full Text] [Related]
36. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Fenaux P; Chastang C; Chomienne C; Castaigne S; Sanz M; Link H; Löwenberg B; Fey M; Archim-Baud E; Degos L
Leuk Lymphoma; 1995 Feb; 16(5-6):431-7. PubMed ID: 7787753
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.
Park KM; Yoo KH; Kim SK; Lee JW; Chung NG; Ju HY; Koo HH; Lyu CJ; Han SM; Han JW; Choi JY; Hong KT; Kang HJ; Shin HY; Im HJ; Koh KN; Kim H; Kook H; Baek HJ; Kim BR; Yang EJ; Lim JY; Park ES; Choi EJ; Park SK; Lee JM; Shim YJ; Kim JY; Park JK; Kong SG; Choi YB; Cho B; Lim YT
Cancer Res Treat; 2022 Jan; 54(1):269-276. PubMed ID: 33887821
[TBL] [Abstract][Full Text] [Related]
38. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Meloni G; Diverio D; Vignetti M; Avvisati G; Capria S; Petti MC; Mandelli F; Lo Coco F
Blood; 1997 Aug; 90(3):1321-5. PubMed ID: 9242568
[TBL] [Abstract][Full Text] [Related]
39. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
Benedetti L; Grignani F; Scicchitano BM; Jetten AM; Diverio D; Lo Coco F; Avvisati G; Gambacorti-Passerini C; Adamo S; Levin AA; Pelicci PG; Nervi C
Blood; 1996 Mar; 87(5):1939-50. PubMed ID: 8634442
[TBL] [Abstract][Full Text] [Related]
40. The molecular biology of acute promyelocytic leukemia.
Slack JL; Gallagher RE
Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
